| scholarly article | Q13442814 |
| P50 | author | Salvatore Carbone | Q56872188 |
| Michael C Kontos | Q90827602 | ||
| P2093 | author name string | Michael J Lipinski | |
| Antonio Abbate | |||
| Christopher Thomas | |||
| Charlotte S Roberts | |||
| Benjamin W Van Tassell | |||
| Dave L Dixon | |||
| Jeremy Turlington | |||
| Ryan Melchior | |||
| Edoardo Bressi | |||
| Cory R Trankle | |||
| Justin M Canada | |||
| Dinesh Kadariya | |||
| Marco Giuseppe Del Buono | |||
| Juan G Chiabrando | |||
| George Mueller | |||
| Sanah Christopher | |||
| Nayef Abouzaki | |||
| James Garnett | |||
| George F Wohlford | |||
| Leo F Buckley | |||
| Giuseppe G Biondi-Zoccai | |||
| Darryn Appleton | |||
| Roshanak Markley | |||
| Laura Puckett | |||
| Chau Vo | |||
| Aaron Schatz | |||
| Horacio Medina de Chazal | |||
| P2860 | cites work | Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure | Q28731260 |
| Cyclosporine before PCI in Patients with Acute Myocardial Infarction | Q34491582 | ||
| The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study | Q35059517 | ||
| National trends in heart failure hospitalization after acute myocardial infarction for Medicare beneficiaries: 1998-2010. | Q35556751 | ||
| Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. | Q36816882 | ||
| Long-term trends in the incidence of heart failure after myocardial infarction | Q37312662 | ||
| Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction | Q38188327 | ||
| Invasive hemodynamic characterization of heart failure with preserved ejection fraction | Q38224332 | ||
| Inflammatory markers in ST-elevation acute myocardial infarction | Q38355385 | ||
| Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease | Q38606033 | ||
| Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy | Q39399883 | ||
| Interleukin-1 Blockade in Acute Decompensated Heart Failure: A Randomized, Double-Blinded, Placebo-Controlled Pilot Study. | Q40780801 | ||
| Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction | Q44558308 | ||
| Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. | Q44938264 | ||
| Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). | Q44956453 | ||
| Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies). | Q45006820 | ||
| Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). | Q45073053 | ||
| The NLRP3 inflammasome in acute myocardial infarction | Q45073088 | ||
| C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction | Q47191457 | ||
| Inhibiting the inflammatory injury following myocardial ischemia reperfusion with plasma derived α-1 anti-trypsin: a post-hoc analysis of the VCU-α1RT study. | Q52596503 | ||
| Rationale and design of the Virginia Commonwealth University-Anakinra Remodeling Trial-3 (VCU-ART3): A randomized, placebo-controlled, double-blinded, multicenter study | Q60177536 | ||
| Effect of Interleukin-1 Blockade on Left Ventricular Systolic Performance and Work: A Post Hoc Pooled Analysis of 2 Clinical Trials | Q60177543 | ||
| Usefulness of Canakinumab to Improve Exercise Capacity in Patients With Long-Term Systolic Heart Failure and Elevated C-Reactive Protein. | Q60177558 | ||
| Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward | Q84587695 | ||
| Interleukin-1 blockade in cardiovascular diseases: a clinical update | Q88189662 | ||
| Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure | Q90759644 | ||
| Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction | Q91304576 | ||
| P433 | issue | 5 | |
| P304 | page(s) | e014941 | |
| P577 | publication date | 2020-03-03 | |
| P1433 | published in | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease | Q19880670 |
| P1476 | title | Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment-Elevation Myocardial Infarction | |
| P478 | volume | 9 |
Search more.